drugset / Trial / NCT01774435

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435

Phase 1 Completed 35 enrolled Endo USA Inc., a Keenova Therapeutics Company
NaSingle-groupOpen-labelTreatment

Summary

This is an study evaluating the safety, tolerability, and PK of EN3342 in implantation durations of 6 months.

Timeline

Start
2012-10
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified Subcutaneous

Indications